was performed by Kaplan-Meier curves and Log-Rank test.Statistical significance was considered for values of p <0.05.Results: PET CT images of 78 patients were centrally reviewed. All patients are currently alive (OS=100%). After a median follow-up of 60 months (range 17-139) 17 patients (21%) had disease recurrence, with RFS of 60% at 104 months (median not reached). The median time to relapse was 8 months (range 3-39). Splenic involvement, anemia (Hb<12 gr/dl) and bulky disease at diagnosis increased risk of relapse. Patients with EoT DS1 (56 cases) showed 83% RFS at 100 months (median not reached). Median RFS worsened for higher DS: 77 months for DS2 (12 cases), 2 months for DS3 (2 cases), 26 months for DS 4 (3 cases), and 14 months for DS5 (p <0.001) [Shown in figure]. There was a longer time frame to relapse in DS1/2 compared to DS≥3 (median time of 34 and 4 months respectively). Comparing I-
8-oxo-2'-désoxyguanosine (8-oxo-dg) (ou 8-hydroxy-désoxyguanosine (8-OHdG)-facteur indépendant du pronostic du déroulement de la maladie chez des patients atteints de cancer colorectal métastatique Introduction. Un traumatisme chirurgical peut stimuler la croissance de la tumeur pendant le cancer colorectal métastatique à la suite de la formation d'un dysfonctionnement mitochondrial. But. Nous avons analysé l`importance clinique du marqueur moléculaire de 8-hydroxydésoxyguanosine (8-OHdG) et l`influence oncologique d`ischémie chaude de parenchyme hépatique. Matériaux et méthodes. L'étude portait sur 89 patients atteints de cancer colorectal atteints de métastase hépatique métastatique traités à l'Institut National du Cancer du Ministère de la Santé, Kiev, Ukraine, de 2015 à 2018, et 19 donneurs sous condition. Le taux de 8-hydroxy-désoxyguanosine (8-OHDGu) dans l'urine des patients atteints de mCRC a été déterminé. La collecte d'urine a été effectuée un jour avant l'opération
This research is relevant, as AL-amyloidosis refers to a systemic type of disease characterised by aggregation of an improperly folded light chain of immunoglobulin, mainly in the heart and kidneys, causing organ failure. This study describes the clinical experience of introducing a patient with cardiac amyloidosis associated with multiple myeloma. A clinical case of a patient diagnosed with amyloidosis was considered. MRI signs of cardiac amyloidosis were confirmed due to the presence of concentric biventricular hypertrophy without dilation, atrial septal hypertrophy, a tendency to atrial dilation, thickening of valve flaps and atrial walls. Upon admission to the research institute, the patient had an anasarca. More accurate recognition of AL-amyloidosis by cardiologists allows prescribing earlier treatment and improving results. Conventional treatment of multiple myeloma and AL-amyloidosis includes a combination of dexamethasone with bortezomib and endoxan. Hematopoietic stem cell transplantation after taking high doses of melphalan has become another treatment option and has led to remission in some patients. The novelty of the study is that an example of a timely complete diagnosis and treatment of a combination of these two diseases was presented, as a result of which the patient has achieved a complete haematological and partial organ response to the underlying disease.
AL-amyloidosis refers to a systemic type of disease characterised by aggregation of an improperly folded light chain of immunoglobulin, mainly in the heart and kidneys, causing organ failure. This study describes the clinical experience of introducing a patient with cardiac amyloidosis associated with multiple myeloma. The diagnosis of amyloidosis is based on a high index of clinical suspicion. Unfortunately, the disease often proceeds asymptomatically until a late stage, and even then the symptoms can be very nonspecific. The prolonged time to establish a diagnosis, often more than 1 year, is a frequent factor in poor treatment results. The slow course of the disease, in most cases, leads to fatal consequences, since initially, patients do not turn to specialised professionals. Namely, congestive heart failure and cardiac arrhythmia are common causes of death from primary systemic amyloidosis, from 48% to 65% of cardiac mortality. More accurate recognition of AL-amyloidosis by cardiologists allows prescribing earlier treatment and improving results. Conventional treatment of multiple myeloma and AL-amyloidosis includes a combination of dexamethasone with bortezomib and endoxan. Hematopoietic stem cell transplantation after taking high doses of melphalan has become another treatment option and has led to remission in some patients. The study presents an example of a timely complete diagnosis and treatment of a combination of these two diseases, as a result of which the patient has achieved a complete haematological and partial organ response to the underlying disease.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.